Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness
Brown A, Wells P, Jaffey J, McGahan L, Poon M-C, Cimon K, Campbell K
Record ID 32007000061
English, French
Authors' objectives:
The objectives were to assess the clinical and economic implications of point-of-care (POC) monitoring devices for long-term oral anticoagulation therapy (OAT).
Authors' recommendations:
1. POC devices can improve health. Using POC devices to manage OAT results in significantly fewer deaths and thromboembolic events, and better INR control than conventional laboratory testing, with no significant difference in hemorrhagic events.
2. POC devices can reduce costs. Compared to laboratory testing, using POC devices in anticoagulation clinics is cost-saving compared with conventional testing for health care payers. It is also cost effective if society is willing to pay 50,000 USD for a quality-adjusted life-year (QALY). Selftesting by patients compared to laboratory testing does not seem to be cost effective from a publicly funded health care perspective.
3. Additional resources are required. Up to 24% of OAT patients in Canada could be eligible for self-testing or self-management with POC devices. The capital outlay for these patients would be 50 million USD and the annual costs for consumables would be 18 million USD.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/H0299_anticoagulation-therapy_tr_e.pdf
Year Published:
2007
URL for published report:
http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/679
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Point-of-Care Systems
- Prothrombin Time
- Anticoagulants
- Blood Coagulation Tests
- Drug Monitoring
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.